Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Ovarian Neoplasms 13Fallopian Tube Neoplasms 12Colorectal Neoplasms 8Melanoma 6Glioblastoma 5Uterine Cervical Neoplasms 4Gliosarcoma 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Brenner Tumor 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrent Squamous Cell Lung Carcinoma 3Rectal Neoplasms 3Prostatic Neoplasms 3Oligodendroglioma 3Colonic Neoplasms 3Brain Neoplasms 3Uveal Melanoma 2Spinal Cord Neoplasms 2Pancreatic Neoplasms 2Medulloblastoma 2Lung Neoplasms 2Glioma 2Carcinoma, Hepatocellular 2Astrocytoma 2Vulvar Neoplasms 1Virus Diseases 1Vipoma 1

Interventions

tremelimumab 1durvalumab 1bintrafusp alfa protein, human 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Anatomic Stage II Breast Cancer AJCC v8 × Immunoglobulin G × Clear all
NCT03132467 2024-06-05

Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Completed
16 enrolled 8 charts
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡